<p>Pranlukast Antagonizes CD49f and Reduces Stemness in Triple-Negative Breast Cancer Cells</p>
نویسندگان
چکیده
منابع مشابه
Association of HDAC8 Expression with Pathological Findings in Triple Negative and Non-Triple Negative Breast Cancer: Implications for Diagnosis
Background: Previous data have shown the tumorigenicity roles of HDAC8 in breast cancer. More recently, the oncogenic effects of this molecule have been revealed in TNBC. The present study aimed to determine the diagnostic value of HDAC8 for the differentiation of TNBC from nTNBC tumors. Methods: A total of 50 cancerous and normal adjacent tumor specimens were obtained, and the clinical and pat...
متن کاملClinicopathological Features of Non-metastatic Triple Negative Breast Cancer
Background: Triple negative breast cancer (TNBC) is reported to be associated with a high risk of recurrence, poor overall survival (OS), and disease-free survival (DFS) rates. This study evaluated the clincopathological features and survival of non-metastatic TNBC women in the capital of Iran compared with other areas of the world. Methods: In a retrospective study, 119 women with TNBC based ...
متن کاملCDK4 regulates cancer stemness and is a novel therapeutic target for triple-negative breast cancer
Triple negative breast cancers exhibit very aggressive features and poor patient outcomes. These tumors are enriched in cancer stem cells and exhibit resistance to most treatments and chemotherapy. In this study, we found the cyclin-dependent kinase (CDK4) to act as a cancer stem cell regulator and novel prognostic marker in triple negative breast cancers. We found CDK4 to be highly expressed i...
متن کاملTriple-Negative Breast Cancer
Triple-negative breast cancer, so called because it lacks expression of the estrogen receptor, progesterone receptor, and HER2, is often, but not always, a basal-like breast cancer. This review focuses on its origin, molecular and clinical characteristics, and treatment.
متن کاملTriple-Negative Breast Cancer
From the Program in Cancer Genetics, the Research Institute of the McGill University Health Centre, and the Lady Davis Institute of the Jewish General Hospital (W.D.F.); McGill University, Montreal; and the Breast Unit, Royal Marsden Hospital and Institute of Cancer Research (I.E.S.), and the Breakthrough Breast Cancer Research Centre, Institute of Cancer Research (J.S.R.-F.) — both in London. ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Drug Design, Development and Therapy
سال: 2020
ISSN: 1177-8881
DOI: 10.2147/dddt.s247730